A Phase 1/2, First-in-human, Open-Label, Dose-Escalation Study of TAK-280, an Investigational B7-H3 X CD3ε Conditional Bispecific Redirected Activation (COBRA) T-cell Engager, in Adult Patients with Unresectable, Locally Advanced, or Metastatic Solid Tumors.